Off-label use of ketamine for treatment-resistant depression in clinical practice: European perspective.
editorial · Level V
Where this comes from
- Record sourced from PubMed, PMID 31030677.
- Also identified by DOI 10.1192/bjp.2019.102.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
Ketamine therapy for treatment-resistant depression in European national health systems may only be considered after attempting all evidence-based antidepressant strategies outlined in clinical guidelines. This paper seeks to explain the ethical, regulatory and procedural framework for the off-label use of ketamine for treatment-resistant depression within a public healthcare system.Declaration of interestNone.
Medical subject headings
- Antidepressive Agents
- Depressive Disorder, Treatment-Resistant
- Ketamine
- Off-Label Use